Manufacturing is a critical step in LBP development that is often
overlooked. Often the focus is directed on the research and initial
phases and not enough attention is directed to the physical and
logistical aspects of creating and producing a pharmaceutical product
en masse. This creates many technological issues and unnecessary
delays when scaling-up becomes a requirement. Servatus has
circumvented this by securing our own private manufacturing facility,
enabling us to test and scale-up production in-house, using our tried
and tested automated and continuous manufacturing process and
proprietary bioprocessing methods.

Controlling production at our facility and using our specially designed bioprocesses means we have been able to develop not only novel LBP
drug variants, but also we have developed our own proprietary media
and production systems, including very low temperature spray drying
for continuous production of high quality live microbial biotherapeutics.

Bio-manufacturing process using a proprietary closed system:
 Continuous production controlled by process automation skids using electrostatic spray drying (ESD) at low temperature which improves both recovery and production costs.

Our proprietary media has been developed for high viable cell density
(>1.0E10 cells/ml) and surpass the high standards of global regulatory compliance.